Feb 15, 2013, 12:38 PM EDT
The NHL is not taking issue with the Vancouver Canucks’ decision to place forward Manny Malhotra on injured reserve, despite the fact the 32-year-old who suffered a serious eye injury in 2011 has appeared in nine games this season.
Deputy commissioner Bill Daly told the Vancouver Sun’s Brad Ziemer that “the league is satisfied and has approved the team’s and player’s joint decision to discontinue the player’s participation in NHL games at this time on the basis of the player’s current medical condition and the risk of injury that such condition poses.”
The Canucks announced the move yesterday, with general manager Mike Gillis suggesting Malhotra’s impaired vision put the veteran player at risk on the ice.
“I have to make the decision and I wouldn’t put anybody in a position (if) I was uncomfortable with their ability to protect themselves,” said Gillis, “or their ability to function out on the ice and be at a higher risk than normal, particularly in today’s game where it so fast, the players are big … I wasn’t prepared to live with that any longer.”
Malhotra is in the final year of a three-year, $7.5 million contract (cap hit $2.5 million).
- ‘Hawks rattle Rask with ‘way more traffic’ in Game 4 0
- Discuss: More Seabrook OT magic ties series 23
- Are the Pens leaning towards trading Letang? (Updated) 65
- Playoffs Tonight: Can ‘Hawks solve Rask? 23
- Sakic: If we keep top pick, we’ll likely draft a forward 25
- Report: Flyers will buy out Briere, Bryzgalov another story (Updated) 37
- Report: Flyers, Ducks talking about Bobby Ryan 60
- Marchand accuses ‘kitty cat’ Shaw of eye gouging 103
- Quenneville says Hossa is ‘likely’ to play Game 4 12
- Datsyuk announces three-year, $22.5 million extension with Red Wings 12
- LIVE: Bruins-Blackhawks, Game 4
- Posnanski: How Heat won a game of mistakes
- PHT: Can Blackhawks solve Rask in Game 4?
- PFT: Report: Hernandez accused of prior shooting
- CSN: Report: Hernandez 'not ruled out' as suspect
- GTC: Tiger pulls out of AT&T citing elbow issue
- HBT: Biogenesis suspensions still likely coming